RemeGen Co Ltd

688331

Company Profile

  • Business description

    RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.

  • Contact

    58 Middle Beijing Road
    Yantai Area of Shandong Pilot Free Trade Zone
    Yantai Development Zone
    Yantai
    CHN

    T: +86 5353573511

    https://www.remegen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    3,070

Stocks News & Analysis

stocks

What does big US court decision mean for Google’s parent company Alphabet?

Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
stocks

Our only 5-star wide moat ASX share

A difficult year but better times ahead.
stocks

Is this still an ASX share to own forever?

Find out how this defensive player has fared after earnings.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,140.5011.000.12%
CAC 407,674.7824.14-0.31%
DAX 4023,596.98173.35-0.73%
Dow JONES (US)45,400.86220.43-0.48%
FTSE 1009,208.218.66-0.09%
HKSE25,417.98359.471.43%
NASDAQ21,700.397.30-0.03%
Nikkei 22543,018.75438.481.03%
NZX 50 Index13,223.5390.330.69%
S&P 5006,481.5020.58-0.32%
S&P/ASX 2008,871.208.600.10%
SSE Composite Index3,812.5146.641.24%

Market Movers